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Abstract
Human papillomaviruses (HPV) are a major cause of malignancy worldwide. They are the
aetiological agents of almost all cervical cancers as well as a sub-set of other anogenital
and head and neck cancers. Hijacking of host cellular pathways is essential for virus patho-
genesis; however, a major challenge remains to identify key host targets and to define their
contribution to HPV-driven malignancy. The Hippo pathway regulates epithelial homeosta-
sis by down-regulating the function of the transcription factor YAP. Increased YAP expres-
sion has been observed in cervical cancer but the mechanisms driving this increase remain
unclear. We found significant down-regulation of the master Hippo regulatory kinase STK4
(also termed MST1) in cervical disease samples and cervical cancer cell lines compared
with healthy controls. Re-introduction of STK4 inhibited the proliferation of HPV positive cer-
vical cells and this corresponded with decreased YAP nuclear localization and decreased
YAP-dependent gene expression. The HPV E6 and E7 oncoproteins maintained low STK4
expression in cervical cancer cells by upregulating the oncomiR miR-18a, which directly tar-
geted the STK4 mRNA 3’UTR. Interestingly, miR-18a knockdown increased STK4 expres-
sion and activated the Hippo pathway, significantly reducing cervical cancer cell
proliferation. Our results identify STK4 as a key cervical cancer tumour suppressor, which is
targeted via miR-18a in HPV positive tumours. Our study indicates that activation of the
Hippo pathway may offer a therapeutically beneficial option for cervical cancer treatment.
Author summary
HPVs are the causative agents of ~5% of human cancers. Better understanding of the
mechanisms by which these viruses deregulate cellular signalling pathways may offer
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therapeutic options for HPV-associated malignancies. The transcription factor YAP is
active in cervical cancer but the mechanisms controlling its activation remain unclear.
YAP is negatively regulated and sequestered in the cytoplasm through activation of the
Hippo pathway. We discovered that expression of the master Hippo kinase, STK4 (also
termed MST1), is reduced in HPV positive cervical cell lines and cervical disease samples.
Low STK4 levels were maintained by the HPV oncogenes through up-regulation of miR-
18a, which targeted the STK4 mRNA 3’UTR. Re-introduction of STK4 or bypassing miR-
18a-dependent regulation de-activated YAP-driven transcription and reduced cell prolif-
eration. Thus, our study identifies a novel interplay between HPV oncogenes and the
STK4 tumour suppressor and identifies the Hippo pathway as a target for therapeutic
intervention in HPV-associated malignancies.
Introduction
Human papillomaviruses (HPV) are a major cause of ano-genital cancers, accounting for
99.9% of all cervical cancer cases, and are linked to an increasing number of head and neck
carcinomas [1–3]. The majority of HPV-associated cancers are associated with infection by
two high-risk (HR) types; HPV16 and HPV18, but other HPV types can also cause cancer. The
main drivers of transformation in HPV-mediated cancers are the E6 and E7 oncoproteins.
These oncoproteins interact with multiple host cell factors to manipulate cellular processes
and promote transformation [4–7].
The Hippo signalling pathway controls organ and tissue homeostasis across diverse species,
through regulation of cellular proliferation and apoptosis [8–10]. In mammals, the core Hippo
pathway is a kinase cascade comprised of the sterile 20-like family kinases serine/threonine
protein kinase 4 (STK4) (also known as MST1) and STK3 (also known as MST2), the large
tumour suppressors (LATS1 and LATS2) and the adaptor proteins Mps One Binder kinase
activator (MOBs) and Salvador homologue 1 (SAV1) [11]. Activation of these kinases results
in serine phosphorylation of the major Hippo targets yes-associated protein (YAP) and its
paralogue the transcriptional co-activator with PDZ-binding (TAZ). This promotes their
interaction with 14-3-3 proteins resulting in cytoplasmic sequestration or phosphorylation-
dependent proteasomal degradation via the ubiquitin proteasome system. However, in their
non-phosphorylated state, YAP and TAZ traffic to the nucleus where they partner with TEAD
transcription factors to regulate the expression of genes necessary for cell proliferation, differ-
entiation and survival [12].
Overexpression and aberrant activation of YAP, likely caused by deregulation of the Hippo
pathway, is observed in most cancers including breast, liver and oesophageal cancer [13–15],
and has been linked to shorter patient survival [16,17]. Moreover, STK4 and STK3 have been
established as tumour suppressor proteins. In mice, ablation of STK4/STK3 expression leads
to hepatocellular carcinoma and intrahepatic cholangiocarcinoma [18]. In colorectal cancers,
STK4 expression has been found to be negatively regulated by the micro-RNA miR-590-3p
[19]. One recent study recommended STK4 as an early biomarker for colorectal cancer and as
a marker of poor prognosis[20].
Stabilisation of YAP has recently been observed in cervical cancer cells [21]. This is medi-
ated by the HPV E6 oncoprotein and results in increased expression of the epidermal growth
factor receptor (EGFR) ligand, amphiregulin (AREG), which in turn was found to further
inhibit the Hippo pathway [21]. Furthermore, the E6 protein from the β genus HPV type 8 can
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induce YAP-dependent gene transcription, and this may be through attenuating the activity of
the Hippo kinase LATS [22].
Clearly, manipulation of Hippo signalling appears vital for HPV pathogenesis; however, the
molecular mechanisms remain unclear. Moreover, the Hippo pathway consists of many pro-
teins beyond YAP, and the importance of these in the context of cervical cancer biology
remains unknown.
To understand how the Hippo pathway may be de-regulated in cervical cancer, we analysed
the expression and activation status of critical components of the pathway in a panel of cervical
cancer cell lines. STK4 protein levels were selectively decreased in HPV positive (HPV+) cervi-
cal cancer cells when compared with normal human keratinocytes (NHKs) or HPV negative
(HPV-) cervical cancer cells. Importantly, STK4 levels were also lower in cytology samples
from patients with cervical disease and in cervical cancer samples compared to healthy con-
trols. Reintroduction of STK4 or STK3, into HPV+ cancer cells inhibited their proliferation,
migration and invasion. Mechanistically, we discovered that in HPV+ cervical cancer cells
HPV E6 and E7 expression led to suppression of STK4 mRNA levels and this was achieved
through an increase in the mature form of miR-18a, which directly targeted the 3’UTR of the
STK4 mRNA. In summary, we have identified that HPV+ cervical cancer cells upregulate an
oncogenic miRNA (oncomiR) to incapacitate the tumour suppressive Hippo pathway and
increase YAP-dependent gene expression and proliferation.
Results
STK4 expression is decreased in HPV+ cervical cancer cell lines
We investigated how the Hippo pathway is regulated in cervical cancer cells by first measuring
the protein expression and enzymatic activity of essential components of the pathway. Com-
pared with normal primary human keratinocytes (NHKs) or the HPV negative (HPV-) cervi-
cal cancer cell line C33A, levels of total YAP and the phosphorylated form of YAP (pYAP1
S127) were significantly increased in HPV positive (HPV+) cells (Fig 1A, quantified in 1B),
consistent with previous studies [21]. In contrast, levels of the STK4 tumour suppressor pro-
tein were significantly reduced in HPV16+ and HPV18+ cell lines compared to NHK cells,
whereas in HPV- C33A cells STK4 protein expression was similar to that observed in NHK
cells (Fig 1A). As expected, the reduction in STK4 protein in the HPV+ cell lines was accompa-
nied by a decrease in phosphorylation of the STK4 substrate MOB1 (Fig 1A).
Importantly, this pattern of STK4 expression was mirrored in cervical liquid based cytology
samples from a cohort of HPV16+ patients representing cervical intraepithelial neoplasia
(CIN) progression, which commonly precedes cervical cancer. CIN1 is thought to represent a
transient HPV infection, while CIN3 represents clinically significant HPV infection that may
progress to cervical cancer [23]. Cytology samples from patients identified as HPV- and show-
ing no signs of cervical disease served as controls in these experiments. By western blot, STK4
protein levels decreased during disease progression through the CIN2 and CIN3 grades (Fig
1C and quantified in 1D). These findings were corroborated using STK4 immunofluorescence
in sections of cervical tissue from low-grade CIN1 and high-grade CIN3 samples, revealing a
marked decrease in STK4 expression in CIN3 in agreement with western blot data (Fig 1E).
Together, these data demonstrate that STK4 protein expression is down-regulated in HPV
+ cervical disease.
STK4 mRNA levels are reduced in HPV+ cervical cancer cells
To understand how STK4 protein levels were reduced in HPV+ cervical cancer cells, we first
measured whether inhibition of protein degradation restored its expression, as HPV E6 has
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Fig 1. STK4 expression is down regulated in HPV+ cervical cancer. A) Representative western blot analysis of a panel of HPV-
and HPV+ cervical cancer cell lines for components of the Hippo pathway. GAPDH served as a loading control. B) Densitometry
analysis of STK4 expression in A from four independent experiments. SiHa p = 0.0087 and CaSKi p = 0.0044; SW756 p = 0.0052 and
HeLa p = 0.0018; C33A p = 0.44 when compared to NHK. C) Representative western blot from cytology samples of CIN lesions of
increasing grade analysed for STK4 expression. GAPDH served as a loading control. D) Scatter plot of densitometry analysis of a
panel of cytology samples. Twenty samples from each clinical grade (Neg, CIN 1–3) were analysed by western blot and densitometry
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previously been shown to stabilise YAP, a downstream target of STK4 [21]. HeLa and CaSKi
cells were incubated with inhibitors of proteasomal (MG132) or lysosomal (Chloroquine) deg-
radation for 8 hours and STK4 protein levels measured by western blot. Neither inhibitor had
a significant impact on STK4 expression over the course of the experiment (Fig 1F and 1G).
Next, we probed for changes in STK4 mRNA levels. Using qRT-PCR, we observed that STK4
mRNA levels were selectively decreased in both HPV16+ and HPV18+ cells compared with
the NHK and C33A cells (Fig 1H). Crucially, a reduction in STK4 mRNA levels was also
observed in cytology samples from patients with CIN2 and CIN3 cervical disease (Fig 1I). To
provide additional evidence of STK4 down-regulation in patients, we mined available microar-
ray databases [24]. From these we observed little change in STK4 levels between normal cervi-
cal epithelia and low-grade squamous intraepithelial lesions (LSIL; comparable to CIN1). In
contrast, we saw a significant decrease in STK4 mRNA expression in high-grade squamous
intraepithelial lesions (HSIL; comparable to CIN3) when compared to low-grade and normal
cervical epithelia (S1A and S1B Fig). Building on this, we were able to show that decreased
STK4 mRNA expression is a common occurance in cervical cancers (S1C–S1E Fig).
STK4 overexpression re-activates Hippo signalling in HPV+ cancer cells
To assess the implications of reduced STK4 expression in HPV+ cervical cancer, STK4 and its
paralogue STK3/MST2 were over-expressed in HeLa and CaSKi cells. STK3 shares 75% simi-
larity to STK4 and the two proteins are thought to share some functions [25]. Transfection of
Myc-tagged STK4 or STK3 increased MOB1 and YAP1 phosphorylation, indicating that their
overexpression activated the Hippo pathway (Fig 2A and S2A Fig). By immunofluorescence
microscopy, cells with re-activated Hippo pathway showed a redistribution of YAP from the
nucleus to the cytoplasm (indicated by the white arrows) (Fig 2B and S2B Fig). Redistribution
of YAP significantly reduced the mRNA levels of a selection of YAP-dependent genes tested
including amphiregulin (AREG), CD133 (PROM1), cyr61 (cyr61) and cyclin D1 (CCND1) (Fig
2C and S2C Fig). Thus, overexpression of STK4/STK3 in HPV+ cervical cancer cells reconsti-
tutes a functionally active Hippo signalling pathway capable of excluding YAP from the
nucleus and reducing YAP-regulated gene expression.
STK4 inhibits proliferation and cell cycle progression of HPV+ cancer cells
The Hippo pathway negatively regulates tumour progression in a number of cancers. Thus, it
was pertinent to investigate the consequences of re-activating Hippo signalling in cervical can-
cer cells by the re-introduction of STK4 or STK3. Compared to controls, overexpression of
either STK4 or STK3 into HeLa and CaSKi cells resulted in a significant decrease in cell prolif-
eration (Fig 2D and S2D Fig). Additionally, expression of either protein suppressed the ability
of HeLa and CaSKi cells to form anchorage-dependent and anchorage-independent colonies
(Fig 2E and 2F and S2E and S2F Fig).
analysis was performed for STK4 expression. CIN1 not significant; CIN2 p = 0.001; CIN3 p = 0.001 when compared with neg
samples. E) Representative immunofluorescence analysis of tissue sections from cervical lesions representing LSIL and HSIL.
Sections were stained for STK4 expression (green) and nuclei were visualised using DAPI (blue). Images were acquired using
identical exposure times. Scale bar, 20 μm. F-G) Representative western blot of proteasome inhibitor MG132 (F) and lysosome
inhibitor chloroquine (G) dose response in HeLa and CaSKi cells. Cell lysates were probed for the expression of STK4. GAPDH was
used as a loading control (N = 3). H) qPCR analysis of STK4 transcript levels in a panel of HPV- and HPV+ cervical cancer cell
lines. U6 expression was used as a loading control (n = 3). SiHa p = 0.01 and CaSKi p = 0.004; SW756 p = 0.001 and HeLa p = 0.05;
C33A p = 0.12 when compared to NHK. I) qPCR analysis of STK4 transcript levels from different CIN grades (n = 5 from each
grade). U6 expression was used as a control. CIN1 not significant; CIN2 p = 4.6x10-7; CIN3 p = 1.1x10-5 when compared to neg
samples. Error bars represent the mean +/- standard deviation. �P<0.05, ��P<0.01, ���P<0.001 (Student’s t-test).
https://doi.org/10.1371/journal.ppat.1008624.g001
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Fig 2. STK4/3 inhibits proliferation and cell cycle progression in HPV+ cervical cancer cells. A) Representative
western blots of STK4/3 overexpression in HeLa cells. Lysates were analysed for the phosphorylation of the STK4/3
substrate MOB1 and the downstream target YAP. The Myc epitope was used to detect successful expression of fusion
proteins. GAPDH was used as a loading control. B) Immunofluorescence analysis of STK4/3 overexpression in HeLa
cells. Cover slips were stained for STK4/3 (red) and YAP (green). Nuclei were visualised using DAPI (blue). Images
were acquired using identical exposure times. Scale bar, 20 μm. C) qPCR analysis of YAP-dependent genes (AREG,
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We assessed the levels of cyclin proteins, which drive cell proliferation, and upon re-activa-
tion of the Hippo pathway cyclin B1 and cyclin D1 protein levels were reduced whilst cyclin
E1 expression remained unchanged (Fig 2G and S2G Fig). Flow cytometry analysis confirmed
that cells over expressing STK4/STK3 accumulated cells in S-phase, with a corresponding
decrease in the number of cells in the G2/M phases, indicating that cells over-expressing
STK4/STK3 have a prolonged S phase (Fig 2H and S2H Fig). Together, these data show that
Hippo re-activation results in a defect in cell proliferation and the ability of HeLa and CaSKi
cells to form colonies in an anchorage dependent or independent manner, highlighting a
potential tumour suppressor role for STK4/STK3 in HPV+ cervical cancer cells.
In contrast, whilst a clear increase in Hippo pathway activity was seen in HPV- C33A cells
over-expressing STK4 and STK3 (S3A–S3C Fig), this had a negligible impact on cell prolifera-
tion, colony formation or cell cycle progression (S3D–S3F Fig). This suggests that the tumour
suppressor activity of STK4/STK3 may be specific to HPV+ cervical cancer cells and warrants
further investigation.
Kinase activity is essential for STK4 tumour suppressor function
To investigate whether kinase activity was required for the anti-proliferative effects of STK4/
STK3 overexpression, we tested the STK specific inhibitor XMU-MP1 [26]. Cells overexpres-
sing STK4 or STK3 were treated with XMU-MP1 (1 μM) for 8 hours prior to analysis. At this
dose and time point, no overall effects on cell viability were observed. XMU-MP1 treatment
reduced MOB1 and YAP phosphorylation, indicating successful inhibition of kinase activity
(Fig 3A and S4A Fig). Crucially, XMU-MP1 treatment of HeLa or CaSKi cells increased YAP
nuclear localisation (Fig 3B and S4B Fig, white arrows) and increased expression of the YAP-
dependent gene product cyclin D1 (Fig 3A and S4A Fig). Confirmatory experiments were per-
formed with catalytically inactive STK4 (K59R) or STK3 (K56R). These mutants were not able
to phosphorylate MOB1 (Fig 4A and S5A Fig) or redistribute YAP from the nucleus to the
cytoplasm (Fig 4B and S5B Fig, white arrows) and failed to reduce cyclin D1 expression (Fig
4A and S5A Fig).
To further assess the importance of STK kinase activity on cervical cancer cell proliferation,
cells overexpressing STK4 or STK3 were incubated with XMU-MP1. XMU-MP1 treatment
abolished the effects on cell proliferation (Fig 3C and S4C Fig) and colony formation (Fig 3D
and 3E and S4D and S4E Fig). Importantly, similar results were observed when the kinase null
mutants were overexpressed in HPV+ cells (Fig 4C–4E and S4C–S4E Fig). These data demon-
strate that the tumour suppressive functions observed in HPV+ cancer cells require catalyti-
cally active STK4/STK3.
HPV oncoproteins are essential but not sufficient to inhibit STK4
expression
The E6 and E7 oncoproteins are key drivers of transformation in HPV+ cervical cancers [27].
We hypothesized that these oncoproteins were responsible for the reduction in STK4 mRNA
PROM1, Cyr61 and CCND1) in HeLa cells overexpressing STK4/3. U6 expression was used as a loading control
(n = 3). D) Growth curve analysis of HeLa cells overexpressing STK4 or STK3 (n = 4). E) Colony formation assay
(anchorage dependent growth) of HeLa cells overexpressing STK4 or STK3 (n = 4). F) Soft agar assay (anchorage
independent growth) of HeLa cells overexpressing STK4 or STK3 (n = 4). G) Representative western blots of HeLa
cells overexpressing STK4 or STK3 analysed for the expression of cyclin proteins. The Myc epitope was used to detect
expression of fusion proteins. GAPDH was used as a loading control. H) Flow cytometric analysis of cell cycle profile
of HeLa cells overexpressing STK4 or STK3. Error bars represent the mean +/- standard deviation of a minimum of
three biological repeats. �P<0.05, ��P<0.01, ���P<0.001 (Student’s t-test).
https://doi.org/10.1371/journal.ppat.1008624.g002
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Fig 3. Inhibition of STK4/3 kinase activity prevents the block on proliferation and tumourigenesis. A) Representative
western blots of STK4/3 overexpression in HeLa cells with or without treatment with XMU-MP1 for 8 hours prior to lysis.
Lysates were analysed for the phosphorylation of the STK4/3 substrate MOB1, the downstream target YAP and the YAP target
gene cyclin D1. The Myc epitope was used to detect fusion protein expression. GAPDH was used as a loading control. B)
Immunofluorescence analysis of STK4/3 overexpression in HeLa cells with or without treatment with XMU-MP1 for 8 hours
PLOS PATHOGENS HPV down-regulates STK4 expression
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levels and subsequent protein expression observed in HPV+ cervical cancer. To investigate
this, we employed an siRNA knockdown strategy in which HPV18+ HeLa or HPV16+ CaSKi
cells were transfected with a pool of siRNAs targeting E6 and E7 [28]. Transfection of these
siRNAs led to a reduction of both the mRNA and protein expression of HPV E6 and E7 in
each cell line (Fig 5A and 5B). Oncoprotein depletion significantly increased STK4 mRNA
expression (Fig 5A) and this corresponded with increased STK4 protein levels in both HPV16
+ and HPV18+ cervical cancer cell lines (Fig 5B and quantification in Fig 5C). These data dem-
onstrate that the HPV oncogenes are required for the down-regulation of STK4 gene expres-
sion observed in cervical cancer cells.
Inhibition of E6/E7 expression has previously been shown to induce apoptosis and cellular
senescence [29]. Additionally, STK4 is activated in response to apoptotic signals and activation
of the DNA damage response (DDR) [30]. To assess if activation of these pathways was
responsible for the induction of STK4 expression, we treated HeLa cells with staurosporine
(apoptosis; [31]), H202 (DNA damage; [32]) or low dose etoposide (DNA damage induced
senescence; [33]) and assessed STK4 mRNA expression. As STK4 can be cleaved upon geno-
toxic stress [34], we did not assess STK4 protein expression. None of the treatments resulted in
a significant change in STK4 mRNA expression, suggesting that the effect of E6/E7 depletion
on STK4 expression was not due to secondary impacts on the induction of apoptosis, the DDR
or DNA damage induced senescence (S6A–S6C Fig). Furthermore, over-expression of p53,
which occurs upon knockdown of E6 [28], also failed to increase STK4 mRNA expression
(S6D Fig).
To determine if ectopic expression of HPV oncoproteins was able to reduce STK4 expres-
sion, we generated HPV- C33A cells stably expressing HPV18 E6 or E7. Overexpression of
either E6 or E7 resulted in a reduction in STK4 mRNA expression by approximately 40% and
50%, respectively (Fig 5D); however, subsequent STK4 protein expression was only reduced by
around 15% with each oncoprotein (Fig 5E). This indicates that viral oncoprotein expression
by itself may not be sufficient to reduce STK4 expression. To assess this further, we analysed
STK4 levels in primary human keratinocytes stably harbouring the HPV18 genome, which we
have previously shown express both the E6 and E7 oncoproteins [5,28]. Whilst YAP levels (Fig
5F and 5G) and YAP-dependent transcriptional activity (Fig 5H) was significantly higher in
keratinocytes containing HPV18 compared to control cells, we were surprised to observe no
significant changes in STK4 expression (Fig 5F and 5G). This finding was not an artefact of
growing the keratinocytes in monolayer culture, as stratification of cultures by organotypic
raft culture which induces keratinocyte differentiation and recapitulates the productive HPV
life cycle also caused little change in STK4 levels (Fig 5I). Taken together, these data suggest
that HPV E6/E7 expression is essential but not sufficient to down-regulate STK4 expression.
They also confirm that YAP is active during the productive HPV life cycle, not just in HPV dis-
ease, but suggest that YAP activation is mediated by a mechanism independent of the loss of
STK4.
prior to analysis. Cover slips were stained for STK4/3 (red) and YAP1 (green). Nuclei were visualised using DAPI (blue).
Images were acquired using identical exposure times. Scale bar, 20 μm. C) Growth curve analysis of HeLa cells overexpressing
STK4/3 with or without treatment with XMU-MP1 for 8 hours prior to re-seeding (n = 3). D) Colony formation assay
(anchorage dependent growth) of HeLa cells overexpressing STK4/3 with or without treatment with XMU-MP1 for 8 hours
prior to re-seeding (n = 3). E) Soft agar assay (anchorage independent growth) of HeLa cells overexpressing STK4/3 with or
without treatment with XMU-MP1 for 8 hours prior to re-seeding (n = 3). Error bars represent the mean +/- standard
deviation of a minimum of three biological repeats. �P<0.05, ��P<0.01, ���P<0.001 (Student’s t-test).
https://doi.org/10.1371/journal.ppat.1008624.g003
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Fig 4. Kinase null STK4/3 mutants do not inhibit proliferation and tumourigenesis. A) Representative western
blots of STK4/3 or kinase dead (KD) STK4/3 overexpression in HeLa cells. Lysates were analysed for the
phosphorylation of the STK4/3 substrate MOB1, the downstream target YAP and the YAP target gene cyclin D1.
Antibodies against STK4/3 were used to detect successful expression. GAPDH was used as a loading control. B)
Immunofluorescence analysis of STK4/3 or KD STK4/3 overexpression in HeLa cells. Cover slips were stained for
STK4/3 (red) and YAP1 (green). Nuclei were visualised using DAPI (blue). Images were acquired using identical
PLOS PATHOGENS HPV down-regulates STK4 expression
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miR-18a is upregulated in HPV+ cervical cancer and directly targets STK4
mRNA
Both HPV E6 and E7 can modulate the microRNA (miRNA) network as a mechanism to con-
trol host gene expression [35–37]. The oncomiR miR-18a, a member of the oncogenic miR-
17-92 cluster, is highly expressed in cervical cancer and has been shown to contribute to the
proliferative and invasive phenotype, through ill-defined mechanisms [38,39]. Bioinformatic
analysis of the STK4 mRNA 3’UTR region revealed a putative miR-18a binding site (Fig 6A).
We first confirmed that miR-18a was up-regulated in our panel of cervical cancer cell lines by
miScript analysis. Compared with NHK and C33A cells, levels of mature miR-18a were
increased in both HPV16+ and HPV18+ cell lines (Fig 6B). In line with this, analysis of cervical
cytology samples highlighted a significant correlation between increased miR-18a levels and
cervical disease progression, which inversely correlated with STK4 expression (Fig 6C and
6D). In agreement with our data, analysis of available microarray datasets showed a significant
increase in miR-18a expression in cervical cancer compared to normal tissue (Fig 6E).
To inhibit miR-18a, cells were transfected with a miR-18a antagomir and STK4 mRNA lev-
els were assessed by qRT-PCR. Inhibition of miR-18a led to a dose-dependent increase in
STK4 mRNA and protein levels in HeLa cells (Fig 6F and 6G). To address if STK4 is a direct
target of miR-18a, HeLa and CaSKi cells were transfected with the miR-18a antagomir and a
reporter plasmid containing a renilla luciferase sequence fused to the STK4 3’UTR. Cells trans-
fected with the miR-18a antagomir showed increased luciferase levels, suggesting that miR-18a
directly regulates STK4 gene expression in HPV+ cervical cancer cells (Fig 6H and S7A Fig).
To confirm that miR-18a acted through the putative miR-18a binding site identified in the
STK4 3’ UTR, we performed site directed mutagenesis to generate a 3’UTR sequence lacking
complementarity to miR-18a (Fig 6A). In contrast to the wild-type, luciferase expression from
the mutant STK4 3’ UTR plasmid was unaffected by the miR-18a antagomir (Fig 6H and S7A
Fig). These data suggest that in HPV+ cervical cancer cells, miR-18a directly regulates STK4
gene expression through binding to the miR-18a binding site within the STK4 3’ UTR.
Given that STK4 expression is regulated by HPV E6/E7, we hypothesised that miR-18a
expression may also in some way be governed by the viral oncoproteins. We depleted E6 and
E7 by siRNA and noted a significant decrease in miR-18a expression, corresponding to the
increase in STK4 expression previously observed (Fig 6I and S7B Fig). Knockdown of E6 and
E7 also caused an increase in luciferase levels driven by the wild-type STK4 3’ UTR luciferase
plasmid but not from the miR-18a binding site mutant plasmid (Fig 6J and S7C Fig). Impor-
tantly, re-introduction of a miR-18a mimic in the E6 and E7 knockdown cells ablated the
increase in luciferase levels (Fig 6J and S7C Fig), STK4 mRNA expression (Fig 6I and S7B Fig)
and STK4 protein expression (Fig 6K and S7D Fig). Interestingly, transfection of a miR-18a
antagomir into HPV- C33A cells did not affect STK4 mRNA expression (S8A Fig), suggesting
that miR-18a does not regulate the Hippo pathway in these cells. Together, these data demon-
strate that the E6 and E7 mediated increase in miR-18a regulates STK4 gene expression by
directly targeting the STK4 3’ UTR.
exposure times. Scale bar, 20 μm. C) Growth curve analysis of HeLa cells overexpressing STK4/3 or KD STK4/3
(n = 3). D) Colony formation assay (anchorage dependent growth) of HeLa cells overexpressing STK4/3 or KD STK4/3
(n = 3). E) Soft agar assay (anchorage independent growth) of HeLa cells overexpressing STK4/3 or KD STK4/3
(n = 3). Error bars represent the mean +/- standard deviation of a minimum of three biological repeats. �P<0.05,
��P<0.01, ���P<0.001 (Student’s t-test).
https://doi.org/10.1371/journal.ppat.1008624.g004
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Fig 5. HR-HPV E6 and E7 oncoproteins suppress STK4 expression. A) qPCR analysis of STK4 transcript levels in HeLa and CaSKi cells
transfected with HPV16 or HPV18 specific E6 and/or E7 siRNA, respectively. U6 was used as a loading control (n = 3). B) Representative
western blots of HeLa and CaSKi cells transfected with HPV16 or HPV18 specific E6 and/or E7 siRNA, respectively, and analysed for STK4
protein expression. GAPDH was used as a loading control. C) Quantification of B from three independent experiments. D) qPCR analysis of
STK4 transcript levels in C33A cells stably expressing HPV18 E6 or E7. U6 was used as a loading control (n = 3). E) Representative western blot
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Inhibition of miR-18a reduces cervical cancer cell proliferation by
activating the STK4—Hippo pathway
We analysed whether miR-18a has a role in regulating cell proliferation, given that STK4 re-
introduction inhibits HPV+ cell proliferation. Introduction of the miR-18a antagomir led to a
significant decrease in cell proliferation and the ability of these cells to form colonies in both
an anchorage dependent and independent manner (Fig 7A–7C). Since miR-18a is documented
to affect expression of a number of tumour suppressive genes, we investigated if the effects of
miR-18a inhibition were dependent on its targeting of STK4 expression. For this, we employed
an siRNA knockdown strategy in which HeLa and CaSKi cells were transfected with a pool of
siRNA targeting STK4 alongside addition of the miR-18a antagomir. Critically, knockdown of
STK4 partially restored cervical cancer cell proliferation, suggesting that the observed effects of
miR-18a inhibition are in part dependant on the inhibition of STK4 gene expression (Fig 7A–
7C).
Next, we analysed the effects of miR-18a on activation of the Hippo pathway. Transfection
of the miR-18a antagomir led to an increase in both MOB1 and YAP phosphorylation (Fig
7D), and these increases were reduced in cells treated with the STK4 specific siRNA. Addition-
ally, knockdown of STK4 expression in combination with inhibition of miR-18a activity
restored expression of YAP-dependent genes compared to inhibition of miR-18a alone (Fig
7E). Together, these data demonstrate that miR-18a activity promotes proliferation in HPV+
cervical cancer by suppressing STK4 gene expression to inactivate the Hippo pathway.
Discussion
Despite the current availability of prophylactic vaccines against HPV, there are no specific
anti-viral therapies for HPV-associated cancers. Therefore, research is still required to under-
stand the virus-host interactions found in these cancers and to identify the host factors essen-
tial for transformation in order to identify targets for therapeutic intervention. Indeed,
targeting host cell proteins by small molecule inhibitors has been utilised as a potential antivi-
ral therapy for a number of diverse viruses, including those associated with cancer develop-
ment [40–42]. The Hippo pathway is deregulated in many cancers [43]. As the canonical
activator of the Hippo pathway STK4 serves as a negative regulator of tumourigenesis, conse-
quently its expression is down-regulated in several cancers [18,20]. In this study, we used a
combination of patient samples and cancer cell lines to provide the first evidence that the loss
of the STK4 is associated with the YAP-mediated proliferation of cervical cancer cells. Levels
of STK4 were selectively reduced in HPV+ cervical cancer lines and these findings were sup-
ported by clinical data, showing that STK4 expression negatively correlates with cervical dis-
ease progression and is markedly down regulated in cervical cancer. Crucially, re-introduction
of STK4 expression in HPV+ cervical lines caused a significant decrease in cell proliferation.
In contrast, overexpression of STK4 had minimal impact on the growth of HPV- cervical can-
cer cells. Given that we observed increased Hippo pathway signalling in all cell lines
of C33A cells stably expressing HPV18 E6 or E7 and analysed for the expression of STK4. HPV18 E6 and E7 expression was confirmed using
antibodies against E6 and E7 and the HA-tag. GAPDH was used as a loading control. F) qPCR analysis of STK4 and YAP1 expression in NHK
and HPV18-containing NHK cells. U6 was used as a loading control (n = 3). G) Representative western blot of STK4 and YAP from NHK and
HPV18-containing NHK cells. GAPDH was used as a loading control. H) qPCR analysis of YAP-dependent gene expression in NHK and
HPV18-containing NHK cells. U6 was used as a loading control (n = 3). Error bars represent the mean +/- standard deviation. �P<0.05,
��P<0.01, ���P<0.001 (Student’s t-test). I) Representative immunofluorescence analysis of sections of organotypic raft cultures of NHK and
HPV18-containing NHK cells. Sections were stained for STK4 expression (green) and nuclei were visualised using DAPI (blue). Images were
acquired using identical exposure times. Scale bar, 20 μm.
https://doi.org/10.1371/journal.ppat.1008624.g005
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Fig 6. miR-18a is upregulated in cervical cancer and directly targets STK4. A) Schematic of STK4 3’UTR showing miR-
18a binding site and mutant miR-18a binding site. B) miScript analysis of miR-18a levels in a panel of cervical cancer cell
lines. snORD68 expression was used as a loading control (n = 3). C) qPCR analysis of STK4 transcript levels from
different CIN grades (n = 5 from each grade). snORD68 expression was used as a loading control. D) Graph showing
correlation between miR-18a and STK4 expression in matched patient samples of cervical disease (n = 15). E) Scatter plot
of data from GSE86100 (normal cervix (n = 26) and cervical cancer (n = 30)) and GSE30656 (normal cervix (n = 10),
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overexpressing STK4, our results suggest that HPV+ cancer cells are particularly sensitive to
re-activation of this pathway.
The Hippo pathway converges to negatively regulate the transcription factor YAP, a key
driver of cell proliferation that is activated in most solid tumours, including cervical cancer
[21]. Both YAP protein levels and activity were markedly increased in HPV+ cervical cancer
cells compared to HPV- cervical cancer cell lines and primary keratinocytes. Importantly,
STK4 overexpression in HPV+ cervical cancer cells led to an inhibition of YAP function, as
seen by the increased YAP phosphorylation and a corresponding decrease in cell proliferation.
These findings indicate that in HPV+ cervical cancer cells YAP activity is sensitive to the levels
of STK4 and that STK4 mediated signalling, most likely through the canonical Hippo pathway,
is a predominant negative regulator of YAP in these cells. In stark contrast, whilst YAP expres-
sion and transcriptional activity were also significantly up-regulated in keratinocytes harbour-
ing HPV18 genomes compared to uninfected donor controls, levels of STK4 were unaffected
by the presence of HPV18. These cell-based studies are supported by patient data, which show
little change in STK4 expression in LSIL biopsies or CIN1 cytology samples compared to
healthy cervical tissue. In patient samples, a significant down-regulation of STK4 was only
observed in CIN2 and CIN3, as well as in cervical cancer. These findings appear paradoxical,
since previous studies show that YAP is predominantly nuclear in HPV16 containing raft cul-
tures, indicative of high YAP activity in these cells [44]. We interpret these findings to suggest
that active YAP may be essential for both productive HPV infection and to drive proliferation
in HPV-associated cancers. However, the mechanisms employed by HPV to circumvent the
normal regulatory barriers on enhanced YAP activity may differ between productive infection
and disease. In primary keratinocytes activation of YAP appears to be independent of a reduc-
tion in STK4 expression, whilst re-expression of this protein in cervical cancer cells is deleteri-
ous to cell proliferation. The necessity for loss of STK4 expression most likely develops during
disease progression and may reflect differences in the signalling circuitry between primary ker-
atinocytes and transformed cells. Further studies will be essential in order to fully dissect the
role of YAP-dependent signalling during the HPV life cycle and in the progression to cancer
development.
The decrease in STK4 levels observed was dependent on HPV oncoprotein expression.
These proteins have well defined roles to inhibit the function of critical tumour suppressors.
Whilst inactivation of pRb and p53 by E6 and E7, respectively, is the defining characteristic of
these proteins [45,46], it is now clear that their loss alone is not sufficient to initiate cervical
cancer [47,48]. These findings highlight the complex nature of virus-mediated transformation
and suggest that perturbation of multiple host factors is required for cervical cancer progres-
sion. We showed that loss of either oncoprotein from cervical cancer cells resulted in the re-
appearance of STK4; however, ectopic expression of the oncoproteins in HPV- cells was not
high-grade cervical intraepithelial neoplasia (CIN2-3) (n = 18) and cervical carcinoma (n = 19)). Arbitrary expression
values for the microRNA expression of miR-18a in each sample were plotted. F) qPCR analysis of STK4 transcript levels
in HeLa cells with increasing doses of miR-18a antagomir (n = 3). G) Representative western blot of HeLa cells with
increasing doses of miR-18a antagomir. Cell lysates were probed for the expression of STK4. GAPDH was used as a
loading control. H) Luciferase reporter assays from HeLa cells cotransfected with miR-18a antagomir and either a wild-
type STK4 3’UTR reporter plasmid or a mutant that lacks the putative miR-18a binding site. Data presented are relative to
an internal firefly luciferase control (n = 3). I) miScript analysis of miR-18a levels in HeLa transfected with specific E6/E7
siRNA with or without a miR-18a mimic. snORD68 was used as a loading control (n = 3). J) Luciferase reporter assays
from HeLa cells cotransfected with specific E6/E7 siRNA, with or without a miR-18a mimic, and either a wild-type STK4
3’UTR reporter plasmid or a mutant that lacks the putative miR-18a binding site. Data presented are relative to an
internal firefly luciferase control (n = 3). K) Representative western blot of HeLa cells cotransfected with specific E6/E7
siRNA, with or without a miR-18a mimic. Cell lysates were probed for the expression of STK4. GAPDH was used as a
loading control. Error bars represent the mean +/- standard deviation. �P<0.05, ��P<0.01, ���P<0.001.
https://doi.org/10.1371/journal.ppat.1008624.g006
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Fig 7. The proliferative defect upon miR-18a inhibition is partially dependent on increased STK4 protein
expression. A) Growth curve analysis of HeLa and CaSKi cells transfected with miR-18a inhibitor, with or without
STK4 siRNA (n = 3). B) Colony formation assay (anchorage dependent growth) of HeLa and CaSKi cells transfected
with miR-18a inhibitor, with or without STK4 siRNA (n = 3). C) Soft agar assay (anchorage independent growth) of
HeLa and CaSKi cells transfected with miR-18a inhibitor, with or without STK4 siRNA (n = 3). D) Representative
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able to fully recapitulate the loss of STK4 observed in cervical cancer cells. Moreover, perturba-
tion of cellular processes manipulated by E6 and E7 such as the level of p53, DNA damage or
cell stress did not alter STK4 expression. Thus, we conclude that in cervical cancer cells the
HPV oncoproteins are necessary but not sufficient for the loss of STK4. Again, these data fit
with our observations in primary keratinocytes, where we observe robust expression of E6 and
E7 [5,28], but little impact on STK4 levels.
To begin to understand how STK4 is controlled in HPV transformed cells we focussed on
miRNAs, given that STK4 expression can be regulated by miRNAs [49–51] and that the HPV
oncoproteins have been reported to alter expression of host miRNAs to promote transforma-
tion [35]. We focused on miR-18a, as this can regulate STK4 gene expression in prostate cancer
and miR-18a is highly expressed in invasive cervical cancer cells [39,49]. We confirmed that
miR-18a is overexpressed in cervical cancer cells and in clinical biopsies of cervical cancer.
Interestingly, miR-18a expression was increased in CIN2 and CIN3, but not CIN1; this is the
opposite trend to STK4. In matched samples, miR-18a expression inversely correlated with
STK4 mRNA expression. Our data is also in line with previous reports demonstrating that
miR-18a expression is significantly increased in cervical cancer, but not in CIN [52]. Further-
more, miR-18a expression is not differentially regulated in keratinocytes harbouring either the
HPV16 or HPV18 genomes [35]. Whilst miR-18a expression may not be significantly altered,
it would still be useful to determine if it is required during the productive HPV life cycle.
Crucially, inhibition of miR-18a using an antagomir resulted in the restoration of STK4
gene expression, activation of the Hippo pathway and a subsequent defect in proliferation in
HPV+ cells. In contrast, miR-18a had no effect on STK4 expression in HPV- C33A cells,
which would indicate cell specific effects of the miRNA. Although mIR-18a has been shown to
target a number of potential tumour suppressor proteins we found that silencing of STK4 par-
tially restored the proliferative ability of HPV+ cells. This would indicate that in these cells
STK4 is the predominant target, although it would be useful to identify the additional mIR-18a
targets that regulate cervical cancer cell proliferation.
To the best of our knowledge, this study is the first to describe the presence of a signalling
pathway in which HPV oncoproteins participate in a process to up-regulate miR-18a in order
to suppress expression of the STK4 tumour suppressor (Fig 8). Whilst suppression of STK4 is
essential for the growth of HPV+ cervical cancer cells, it appears non-essential in driving YAP-
dependent signalling in primary keratinocytes harbouring the HPV18 genome. A picture is
emerging in which the HPV life cycle and pathogenesis are dependent on manipulation of the
Hippo pathway, which can be targeted through multiple means [53]. Therefore, targeting of
this pathway may serve as a new therapeutic target in the treatment of HPV-associated
malignancies.
Materials and methods
Cervical cytology samples
Cervical cytology samples were obtained from the Scottish HPV Archive (http://www.shine/
mvm.ed.ac.uk/archive.shtml), a biobank of over 20,000 samples designed to facilitate HPV
research. The East of Scotland Research Ethics Service has given generic approval to the
western blots of HeLa and CaSKi cells transfected with miR-18a inhibitor, with or without STK4 siRNA. Lysates were
analysed for STK4, the phosphorylation of the STK4 substrate MOB1, the downstream target YAP and the YAP target
gene cyclin D1. GAPDH was used as a loading control. E) qPCR analysis of YAP dependent gene transcripts in HeLa
and CaSKi cells transfected with miR-18a inhibitor, with or without STK4 siRNA (n = 3). Error bars represent the
mean +/- standard deviation of a minimum of three biological repeats. �P<0.05, ��P<0.01, ���P<0.001.
https://doi.org/10.1371/journal.ppat.1008624.g007
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Scottish HPV Archive as a Research Tissue Bank (REC Ref 11/AL/0174) for HPV related
research on anonymised archive samples. Samples are available for the present project though
application to the Archive Steering Committee (HPV Archive Application Ref 0034). RNA
and protein were extracted from the samples using Trizol as described by the manufacturer
(ThermoFischer Scientific, USA) and analysed as described.
HPV positive biopsy samples
Archival paraffin-embedded cervical biopsy samples were obtained with informed consent.
Subsequent analysis of these samples was performed in accordance with approved guidelines,
which were approved by Glasgow Royal Infirmary: RN04PC003. HPV presence was confirmed
by PCR using GP5+/GP6+ primers.
Cell culture
HeLa (HPV18+ cervical epithelial adenocarcinoma cells), SW756 (HPV18+ cervical squamous
carcinoma cells), SiHa (HPV16+ cervical squamous carcinoma cells), CaSKi (HPV16+ cervical
squamous carcinoma cells) and C33A (HPV- cervical squamous carcinoma) cells obtained
from the ATCC were grown in DMEM supplemented with 10% FBS (ThermoFischer Scien-
tific, USA) and 50 U/mL penicillin. Primary normal human keratinocytes (NHKs) were main-
tained in serum free medium (SFM; GIBCO, UK) supplemented with 25 μg/mL bovine
pituitary extract (GIBCO, UK) and 0.2 ng/mL recombinant EGF (GIBCO, UK). All cells were
cultured at 37˚C and 5% CO2. Primary keratinocytes and HPV18-containing keratinocytes
were created and cultured as previously described [28]. Cells were negative for Mycoplasma
during this investigation. Cell identify was confirmed by STR profiling.
Fig 8. Schematic of HPV-mediated deregulation of the Hippo pathway. Expression of HPV oncoproteins in concert with
changes to the host cell upregulates miR-18a expression, which directly targets the STK4 3’UTR to inhibit STK4 expression.
Loss of STK4 correlates with inhibition of the Hippo pathway and activation of the YAP transcription factor, culminating in
increased YAP-dependent transcription. Image was generated using BioRENDER.com.
https://doi.org/10.1371/journal.ppat.1008624.g008
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Plasmids and inhibitors
pIC-STK4-Myc and pIC-STK3-Myc were provided by Steve Cohen, LMCB, Singapore.
pJ3M-STK4 K59R (Addgene plasmid # 12204) and pJ3H-STK3 K56R (Addgene plasmid #
12206) were purchased from Addgene (Cambridge, MA, USA). pcDNA-p53 was a kind gift
from Olivier Terrier (CIRI, France) The psiCheck2 plasmid was provided by Dr James Boyne
(University of Huddersfield, UK). The STK4 3’UTR was identified used NCBI data using the
AceView program. It was subsequently amplified from HeLa cells and cloned into psiCheck2
using XhoI and NotI. Codon optimized HPV18 E6 and E7 sequences were cloned into
pMSCV-N-HA-IRES-Puro as XhoI-NotI fragments (plasmid kindly provided by Elizabeth
White, University of Pennsylvania). The small molecule inhibitor XMU-MP1 was purchased
from Selleckchem and used at a final concentration of 1 μM[26]. Staurosporine, etoposide and
hydrogen peroxide (H2O2) were purchased from Calbiochem and used at the concentrations
indicated.
siRNA and antagomir
The HPV16 E6 siRNA was purchased form Santa Cruz Biotechnology (USA) and had the fol-
lowing sequence: 5’–UGUGUACUGCAAGCAACAG– 3’. The HPV18 E6 siRNAs were pur-
chased from Dharmacon (GE Healthcare, USA) and had the following sequences: 5’–CUA
ACACUGGGUUAUACAA– 3’ AND 5’–CTAACTAACACTGGGTTAT– 3’. The HPV16 and
HPV18 E7 siRNA were as previously described [54,55]. The STK4 siRNAs were purchased
from Qiagen (FlexiTube GeneSolution GS6789 for STK4; SI02637145, SI02637138, SI000
86870, SI00086863).
Transfections and mammalian cell lysis
Transfection of plasmid DNA was performed with a DNA to Lipofectamine1 2000 (Thermo-
Fischer) ratio of 1:2.5. 48 hr post transfection, cells were lysed in lysis buffer for western blot
analysis, processed for RNA extraction or reseeded into new plates for growth curve analysis,
colony formation assays or soft agar assays. Transfection of siRNAs was performed with an
RNA to Lipofectamine 2000 ratio of 1:2. 72 hr post transfection cells were lysed in lysis buffer
for western blot analysis [28], processed for RNA extraction or reseeded into new plates for
growth curve analysis, colony formation assays or soft agar assays. Transfection of miR-18a
antagomir was performed with an RNA to Lipofectamine 2000 ratio of 1:2. 24 hr post transfec-
tion cells were lysed in lysis buffer for western blot analysis [28], processed for RNA extraction
or reseeded into new plates for growth curve analysis, colony formation assays or soft agar
assays.
Western blot analysis
Equal amounts of protein from cell lysates were separated by SDS PAGE and transferred onto
a nitrocellulose membrane by a semi-dry transfer method (Trans Blot SD Semi-Dry Transfer
cell, Bio-Rad, USA). Membranes were blocked with 5% milk solution before incubation with
primary antibodies at 1:1000 dilution unless otherwise stated: p-YAP1 Ser-127 (CST; D9W2I),
YAP1 (CST; D8H1X), p-MOB1 (CST; D2F1O), MOB1 (CST; E1N9D), STK4 (Abcam; ab51
134) (1:2000), STK3 (Abcam; ab52641) (1:5000), Myc (9E10), Cyclin B1 (Santa Cruz Biotech-
nology (SCBT); sc-245), Cyclin D1 (Abcam; ab13475), Cyclin E (Thermofisher; 32–1600),
HPV 16/18 E6 (CBT; sc-460), HPV 16 E7 (SCBT; sc-1587), HPV 18 E7 (Abcam; ab100953),
and GAPDH (SCBT; sc365062) (1:5000) as a loading control. Horseradish peroxidase (HRP)-
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conjugated secondary antibodies (Sigma, USA) were used at a 1:5000 dilution. Proteins were
detected using WesternBright ECL (Advansta, USA) and visualised on X-ray film.
RNA extraction, cDNA synthesis and quantitative Real Time-PCR
Total RNA was extracted from cells using an E.Z.N.A Total RNA Kit I (omegabiotek). cDNA
was synthesised using 1 μg of RNA and iScript cDNA synthesis kit (Bio Rad). qRT-PCR was
performed on the synthesised cDNA on a Corbett Rotor-Gene 6000 using QuantiFast SYBR
Green PCR kit (Qiagen) and analysed using the ΔΔCT method [56] normalised to the U6
housekeeping gene. Each experiment was repeated at least 3 times. Primer sequences are in
Table 1. For miScript, cDNA was synthesised using 1μg of RNA and miScript II RT Kit (Qia-
gen). qRT-PCR was performed using miScript SYBR Green PCR Kit (Qiagen) and analysed
using the ΔΔCT method [56] normalised to SNORD68 control gene.
Colony formation assay
48 hr post-transfection, cells were trypsinised and reseeded in a six well plate at 500 cells per
well and left to incubate for 14–21 days. Colonies were then stained (1% crystal violet, 25%
methanol) and colonies were counted manually. Each experiment was repeated a minimum of
3 times.
Soft agar assay
Cells were transfected as required. 60 mm dishes were coated with a layer of 1% agarose (Ther-
moFischer Scientific, USA) in 2X DMEM (ThermoFischer Scientific, USA) supplemented
with 20% FBS. 48 hr post-transfection, cells were trypsinised and added to 0.7% agarose in 2X
DMEM (ThermoFischer Scientific, USA) supplemented with 20% FBS at 1000 cells/mL. Once
set, DMEM supplemented with 10% FBS and 50 U/mL penicillin was added. The plates were
then incubated for 14–21 days. Each experiment was repeated at least three times unless stated
otherwise. Visible colonies were counted manually.
Flow cytometry
Cells were transfected as required. 48 hr post-transfection, cells were harvested and fixed in
70% ethanol overnight. The ethanol was removed and cells washed with PBS containing 0.5%
(w/v) BSA. Cells were stained with PBS containing 0.5% BSA, 50 μg/mL propidium iodide
(Sigma) and 5 μg/mL RNase (Sigma) and incubated in this solution for 30 min at room
Table 1. qRT-PCR rimers used in this study.
Gene Forward primer sequence Reverse primer sequence
U6 CTCGCTTCGGCAGCACA AACGCTTCACGCATTTGC
STK4 GCTTCTGACTCAATGCTTAG CCACATCCTCCTGCCAAG
AREG GTGGTGCTGTCGCTCTTGATA ACTCACAGGGGAAATCTCACT
Cyr61 AGCCTCGCATCCTATACAACC TTCTTTCACAAGGCGGCACTC
PROM1 TGGATGCAGAACTTGACAACGT ATACCTGCTACGACAGTCGTGGT
CCND1 CCGCTGGCCATGAACTACCT ACGAAGGTCTGCGCGTGTT
HPV16 E6 CTGCAATGTTTCAGGACCCAC GTTGTTTGCAGCTCTGTGCAT
HPV16 E7 ATTAAATGACAGCTCAGAGGA GCTTTGTACGCACAACCGAAGC
HPV18 E6 TGGCGCGCTTTGAGGA TGTTCAGTTCCGTGCACAGATC
HPV18 E7 GACCTAAGGCAACATTGCA GCTCGTGACATAGAAGGTC
https://doi.org/10.1371/journal.ppat.1008624.t001
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temperature. Samples were processed on an LSRFortessaTM cell analyzer (BD) and the PI his-
tograms analysed on modifit software. Each experiment was repeated a minimum of 3 times.
Microarray analysis
For microarray analysis of STK4 expression, the following datasets were used: GSE6791,
GSE9750, GSE27678, GSE39001 and GSE75132. For microarray analysis of miR-18a expres-
sion, the following datasets were used: GSE30656 and GSE86100.
Immunofluorescence analysis
Cells were seeded onto coverslips and, 24 hr later, were transfected as required. 24 hr after
transfection, cells were fixed with 4% paraformaldehyde for 10 min and then permeabilised
with 0.1% (v/v) Triton for 15 minutes. Cells were then incubated in primary antibodies in PBS
with 4% BSA overnight at 4ºC. Primary antibodies were used at a concentration of 1:400. Cells
were washed thoroughly in PBS and then incubated with Alex-fluor conjugated secondary
antibodies 594 and Alexa 488 (1:1000) (Invitrogen) in PBS with 4% BSA for 2 hours. DAPI
was used to visualise nuclei. Coverslips were mounted onto slides with Prolong Gold
(Invitrogen).
Statistical analysis
Unless otherwise indicated, data was analysed using a two-tailed, unpaired Student’s t-test.
Supporting information
S1 Fig. STK4 expression in cervical cancer cases from the GEO repository. A) Scatter dot
plot of data acquired from the dataset GSE27678. Arbitrary values for the mRNA expression of
STK4 in normal cervix (n = 12), LSIL (n = 11) and HSIL (n = 21) samples were plotted. Normal
vs LSIL, p = 0.80; Normal vs HSIL, p = 0.006; LSIL vs HSIL, p = 0.003. B) Scatter dot plot of
data acquired from the dataset GSE75132. Arbitrary values for the mRNA expression of STK4
in normal cervix (n = 21), LSIL (n = 4) and HSIL (n = 16) samples were plotted. Normal vs
LSIL, p = 0.57; Normal vs HSIL, p = 0.007; LSIL vs HSIL, p = 0.054. C) Scatter dot plot of data
acquired from the dataset GSE6791 on the GEO database. Arbitrary values for the mRNA
expression of STK4 in normal cervix (n = 8) and cervical cancer (n = 20) samples were plotted;
Normal vs cancer, p = 0.002. D) Scatter dot plot of data acquired from the dataset GSE9750 on
the GEO database. Arbitrary values for the mRNA expression of STK4 in normal cervix
(n = 23) and cervical cancer (n = 28) samples were plotted; Normal vs cancer, p = 0.001. E)
Scatter dot plot of data acquired from the dataset GSE39001 on the GEO database. Arbitrary
values for the mRNA expression of STK4 in normal cervix (n = 12) and cervical cancer
(n = 43) samples were plotted; Normal vs cancer, p = 0.02. Error bars represent the mean +/-
standard deviation. �P<0.05, ��P<0.01, ���P<0.001 (Student’s t-test).
(TIF)
S2 Fig. STK4/3 inhibits proliferation and cell cycle progression in HPV16+ cervical cancer
cells. A) Representative western blots of STK4/3 overexpression in CaSKi cells. Lysates were
analysed for the phosphorylation of the STK4/3 substrate MOB1 and the downstream target
YAP. The Myc epitope was used to detected successful expression of fusion proteins. GAPDH
was used as a loading control. B) Immunofluorescence analysis of STK4/3 overexpression in
CaSKi cells. Cover slips were stained for STK4/3 (red) and YAP1 (green). Nuclei were visual-
ised using DAPI (blue). Images were acquired using identical exposure times. Scale bar,
20 μm. C) qPCR analysis of YAP-dependent genes (AREG, PROM1, Cyr61 and CNND1) in
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CaSKi cells overexpressing STK4/3. U6 expression was used as a loading control (n = 3). D)
Growth curve analysis of CaSKi cells overexpressing STK4/3. E) Colony formation assay
(anchorage dependent growth) of CaSKi cells overexpressing STK4/3 (n = 3). F) Soft agar
assay (anchorage independent growth) of CaSKi cells overexpressing STK4/3 (n = 3). G) Rep-
resentative western blots of CaSKi cells overexpressing STK4/3 analysed for the expression of
cyclin proteins. The Myc epitope was used to detect successful expression of fusion proteins.
GAPDH was used as a loading control. H) Flow cytometric analysis of cell cycle profile of
CaSKi cells overexpressing STK4/3. Error bars represent the mean +/- standard deviation of a
minimum of three biological repeats. �P<0.05, ��P<0.01, ���P<0.001 (Student’s t-test).
(TIF)
S3 Fig. STK4/3 does not inhibit proliferation and cell cycle progression in C33A cells. A)
Representative western blots of STK4/3 overexpression in C33A cells. Lysates were analysed
for the phosphorylation of the STK4/3 substrate MOB1 and the downstream target YAP. The
Myc epitope was used to detect successful expression of fusion proteins. GAPDH was used as a
loading control. B) Immunofluorescence analysis of STK4/3 overexpression in C33A cells.
Cover slips were stained for STK4/3 (red) and YAP (green). Nuclei were visualised using
DAPI (blue). Images were acquired using identical exposure times. Scale bar, 20 μm. C) qPCR
analysis of YAP-dependent genes (AREG, PROM1, Cyr61 and CNND1) in C33A cells overex-
pressing STK4/3. U6 expression was used as a loading control (n = 3). D) Growth curve analy-
sis of C33A cells overexpressing STK4/3. E) Colony formation assay (anchorage dependent
growth) of C33A cells overexpressing STK4/3 (n = 3). F) Flow cytometric analysis of cell cycle
profile of C33A cells overexpressing STK4/3. Error bars represent the mean +/- standard devi-
ation of a minimum of three biological repeats. �P<0.05, ��P<0.01, ���P<0.001 (Student’s t-
test).
(TIF)
S4 Fig. Inhibition of STK4/3 kinase activity prevents the block on proliferation and
tumourigenesis in HPV16+ cervical cancer cells. A) Representative western blots of STK4/3
overexpression in CaSKi cells with or without treatment with XMU-MP1 for 8 hours prior to
lysis. Lysates were analysed for the phosphorylation of the STK4/3 substrate MOB1, the down-
stream target YAP and the YAP target gene cyclin D1. GAPDH was used as a loading control.
B) Immunofluorescence analysis of STK4/3 overexpression in CaSKi cells with or without
treatment with XMU-MP1 for 8 hours prior to analysis. Cover slips were stained for STK4/3
(red) and YAP1 (green). Nuclei were visualised using DAPI (blue). Images were acquired
using identical exposure times. Scale bar, 20 μm. C) Growth curve analysis of CaSKi cells over-
expressing STK4/3 with or without treatment with XMU-MP1 for 8 hours prior to re-seeding
(n = 3). D) Colony formation assay (anchorage dependent growth) of CaSKi cells overexpres-
sing STK4/3 with or without treatment with XMU-MP1 for 8 hours prior to re-seeding
(n = 3). E) Soft agar assay (anchorage independent growth) of CaSKi cells overexpressing
STK4/3 with or without treatment with XMU-MP1 for 8 hours prior to re-seeding. Error bars
represent the mean +/- standard deviation of a minimum of three biological repeats. �P<0.05,
��P<0.01, ���P<0.001 (Student’s t-test).
(TIF)
S5 Fig. Kinase null STK4/3 mutants cannot inhibit proliferation and tumourigenesis in
HPV16+ cervical cancer cells. A) Representative western blots of STK4/3 or KD STK4/3 over-
expression in CaSKi cells. Lysates were analysed for the phosphorylation of the STK4/3 sub-
strate MOB1, the downstream target YAP and the YAP target gene cyclin D1. Antibodies
against STK4/3 were used to detect successful expression of fusion proteins. GAPDH was used
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as a loading control. B) Immunofluorescence analysis of STK4/3 or KD STK4/3 overexpres-
sion in CaSKi cells. Cover slips were stained for STK4/3 (red) and YAP (green). Nuclei were
visualised using DAPI (blue). Images were acquired using identical exposure times. Scale bar,
20 μm. C) Growth curve analysis of CaSKi cells overexpressing STK4/3 or KD STK4/3 (n = 3).
D) Colony formation assay (anchorage dependent growth) of CaSKi cells overexpressing
STK4/3 or KD STK4/3 (n = 3). E) Soft agar assay (anchorage independent growth) of CaSKi
cells overexpressing STK4/3 or KD STK4/3 (n = 3). Error bars represent the mean +/- standard
deviation of a minimum of three biological repeats. �P<0.05, ��P<0.01, ���P<0.001 (Student’s
t-test).
(TIF)
S6 Fig. Genotoxic stress does not induce STK4 expression. A) qPCR analysis of STK4 expres-
sion in HeLa cells treated with Staurosporine (50 μM) for 48 hours. U6 expression was used as
a loading control (n = 3). B) qPCR analysis of STK4 expression in HeLa cells treated with
H2O2 (200 μM) for 48 hours. U6 expression was used as a loading control (n = 3). C) qPCR
analysis of STK4 expression in HeLa cells treated with Etoposide (2 μM) for 48 hours. U6
expression was used as a loading control (n = 3). D) qPCR analysis of STK4 expression in
HeLa cells transfected with pcDNA-p53 for 48 hours. U6 expression was used as a loading con-
trol (n = 3). E) Representative western blot of HeLa cells transfected with pcDNA-p53 for 48
hours. Cell lysates were probed for the expression of p53. GAPDH was used as a loading con-
trol. Error bars represent the mean +/- standard deviation of a minimum of three biological
repeats. �P<0.05, ��P<0.01, ���P<0.001.
(TIF)
S7 Fig. miR-18a directly regulates STK4 in HPV16+ cervical cancer cells. A) Luciferase
reporter assays from CaSKi cells cotransfected with miR-18a antagomir and either a wild-type
STK4 3’UTR reporter plasmid or a mutant that lacks the putative miR-18a binding site. Data
presented are relative to an internal firefly luciferase control (n = 3). B) miScript analysis of
miR-18a levels in CaSKi transfected with specific E6/E7 siRNA with or without a miR-18a
mimic. snORD68 was used as a loading control. STK4 expression was also analysed. U6 was
used as a loading control (n = 3). C) Luciferase reporter assays from CaSKi cells cotransfected
with specific E6/E7 siRNA, with or without a miR-18a mimic, and either a wild-type STK4
3’UTR reporter plasmid or a mutant that lacks the putative miR-18a binding site. Data pre-
sented are relative to an internal firefly luciferase control (n = 3). D) Representative western
blot of CaSKi cells cotransfected with specific E6/E7 siRNA, with or without a miR-18a mimic.
Cell lysates were probed for the expression of STK4. GAPDH was used as a loading control.
Error bars represent the mean +/- standard deviation of a minimum of three biological repeats.
�P<0.05, ��P<0.01, ���P<0.001.
(TIF)
S8 Fig. miR-18a does not effect STK4 in C33A cells. A) qPCR analysis of STK4 transcript lev-
els in C33A cells transfected with an miR-18a antagomir (80 nM). U6 was used as a loading
control (n = 3). Error bars represent the mean +/- standard deviation of a minimum of three
biological repeats. �P<0.05, ��P<0.01, ���P<0.001.
(TIF)
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